On Friday, Owens & Minor Inc. (NYSE:OMI) reported that the second quarter of 2024 adjusted EPS of $0.36, double the $0.18 reported a year ago, beating the consensus of $0.33.
The company reported sales of $2.671 billion, up 4% year-over-year, almost in line with the consensus of $2.646 billion.
Patient Direct revenue of $660 million, up 4% compared to the second quarter of 2023, driven by continued strong growth in diabetes and sleep supplies.
Products & Healthcare Services revenue of $2.0 billion, up 4% compared to the second quarter of 2023, driven by strong same-store sales and new wins in the Medical Distribution division.
Operating income of $20.3 million and adjusted operating income of $76.3 million increased by 87% and 23%, respectively, in the second quarter of 2024.
Adjusted EBITDA increased 12% to $127 million, with an operating cash flow of $116 million for the second quarter of 2024.
Guidance: Owens & Minor reaffirms 2024 revenue guidance of $10.5 billion-$10.9 billion versus the consensus of $10.665 billion.
The company expects 2024 adjusted EPS of $1.40-$1.70 versus the consensus of $1.55.
Price Action: OMI stock was trading lower by 3.90% to $15.78 premarket at the last check on Friday.
Read Next:
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.